CA2873653A1 - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents

Process for making hydroxylated cyclopentylpyrimidine compounds Download PDF

Info

Publication number
CA2873653A1
CA2873653A1 CA2873653A CA2873653A CA2873653A1 CA 2873653 A1 CA2873653 A1 CA 2873653A1 CA 2873653 A CA2873653 A CA 2873653A CA 2873653 A CA2873653 A CA 2873653A CA 2873653 A1 CA2873653 A1 CA 2873653A1
Authority
CA
Canada
Prior art keywords
formula
compound
salt
methyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873653A
Other languages
English (en)
French (fr)
Inventor
Jonathan W. LANE
Travis Remarchuk
Sagar Shakya
Keith L. Spencer
Peter J. Stengel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CA2873653A1 publication Critical patent/CA2873653A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2873653A 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds Abandoned CA2873653A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US61/648,421 2012-05-17
US201361785281P 2013-03-14 2013-03-14
US61/785,281 2013-03-14
PCT/US2013/041624 WO2013173736A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (1)

Publication Number Publication Date
CA2873653A1 true CA2873653A1 (en) 2013-11-21

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873653A Abandoned CA2873653A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Country Status (18)

Country Link
US (1) US9309204B2 (https=)
EP (1) EP2861583B1 (https=)
JP (1) JP6214636B2 (https=)
KR (1) KR20150020211A (https=)
CN (1) CN104487430B (https=)
AU (1) AU2013262568B2 (https=)
BR (1) BR112014028570A2 (https=)
CA (1) CA2873653A1 (https=)
DK (1) DK2861583T3 (https=)
ES (1) ES2588878T3 (https=)
IL (1) IL235714A0 (https=)
MA (1) MA37649B1 (https=)
MX (1) MX2014013865A (https=)
PL (1) PL2861583T3 (https=)
RU (1) RU2014151017A (https=)
SG (1) SG11201407613RA (https=)
SI (1) SI2861583T1 (https=)
WO (1) WO2013173736A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350443B (es) 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
HRP20200992T1 (hr) 2012-05-17 2020-10-16 Genentech, Inc. Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci
AU2013262505B2 (en) 2012-05-17 2017-09-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
ES2765511T3 (es) 2013-11-15 2020-06-09 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
SG11201601813UA (en) * 2013-11-27 2016-04-28 Sunshine Lake Pharma Co Ltd Processes for preparing dihydropyrimidine derivatives and intermediates thereof
ES2749100T3 (es) * 2014-09-26 2020-03-19 Hoffmann La Roche Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
IL295929A (en) 2020-06-16 2022-10-01 Hoffmann La Roche Process for making hydroxylated cyclopentylpyrimidine compounds
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506369A (ja) 1993-12-12 1997-06-24 アグロジーン・リミテッド 菌類感染から植物を保護するための新規方法
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1178931C (zh) * 1999-06-03 2004-12-08 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
JP4550811B2 (ja) 2003-06-09 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パピローマウイルスのインヒビター
CA2546754A1 (en) 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
CN101918373B (zh) * 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
EP2209775A1 (en) 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
NZ586346A (en) * 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
MX2012004780A (es) 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
AU2013262505B2 (en) 2012-05-17 2017-09-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
MX350443B (es) 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014150395A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
JP6214636B2 (ja) 2017-10-18
MX2014013865A (es) 2015-05-07
EP2861583A1 (en) 2015-04-22
CN104487430A (zh) 2015-04-01
US20150099881A1 (en) 2015-04-09
AU2013262568A1 (en) 2015-01-22
RU2014151017A (ru) 2016-07-10
SG11201407613RA (en) 2015-01-29
IL235714A0 (en) 2015-02-01
PL2861583T3 (pl) 2016-12-30
KR20150020211A (ko) 2015-02-25
AU2013262568B2 (en) 2017-08-31
HK1208673A1 (en) 2016-03-11
MA37649B1 (fr) 2017-03-31
EP2861583B1 (en) 2016-06-29
MA37649A1 (fr) 2016-06-30
WO2013173736A1 (en) 2013-11-21
US9309204B2 (en) 2016-04-12
DK2861583T3 (en) 2016-10-03
CN104487430B (zh) 2016-08-24
SI2861583T1 (sl) 2016-10-28
JP2015518837A (ja) 2015-07-06
ES2588878T3 (es) 2016-11-07
BR112014028570A2 (pt) 2018-04-24

Similar Documents

Publication Publication Date Title
DK2861583T3 (en) METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER
CA2873661C (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
CA2873654C (en) Process for making hydroxylated cyclopentylpyrimidine compounds
US9278917B2 (en) Process for making amino acid compounds
AU2019253849B2 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208673B (en) Process for making hydroxylated cyclopentylpyrimidine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180517